Sjogren’s syndrome – Market Insights, Epidemiology, and Market Forecast - 2030

DelveInsight’s ‘Sjogren’s syndrome (SS) – Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Sjogren’s syndrome (SS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Sjogren’s syndrome (SS) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted SS symptoms market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Sjogren’s syndrome (SS) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Sjogren’s syndrome (SS) Disease Understanding and Treatment Algorithm
Sjogren’s syndrome (SS) Overview
Sjogren’s syndrome (SS) is an autoimmune disorder caused by the lymphocytic infiltration of exocrine glands resulting in glandular dysfunction, preferentially of the salivary and lacrimal glands. It can be classified into two types, i.e., primary Sjogren’s syndrome, and secondary Sjogren’s syndrome. Primary Sjogren’s syndrome (pSS) occurs in the absence of other autoimmune diseases and is characterized by keratoconjunctiva sicca (dry eyes) and xerostomia (dry mouth), collectively called the sicca syndrome. In contrast, secondary Sjogren’s syndrome presents, along with other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
Currently, the pathogenesis of the diseases is not fully understood and is currently thought to be the result of a combination of factors such as genetic defects, immune mechanisms, and virus infections. Increased activation of B cells followed by immune complex formation and autoantibody production, in particular, anti-Ro/SS-A and anti-La/SS-B are thought to play important roles.
Sicca symptoms are the hallmarks of the disease, which may also present with various organ manifestations. There is no single disease-specific diagnostic criterion for SS. The diagnosis of SS is a complex task that cannot be readily done. No sign, symptom, or test is unique to this syndrome. The diagnosis of SS is based on the combination of sicca symptoms and the presence of the autoimmune phenomena characterized by the activation of T and/or B cells. Also, for many years the diagnosis of SS lacked standardization
The diagnosis of SS is made based on medical history, physical examination, specific ocular, oral evaluation, blood tests, and salivary gland assessment (biopsy and ultrasound).
Sjogren’s syndrome (SS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Sjogren’s syndrome (SS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Sjogren’s syndrome (SS) market report gives a thorough understanding of SS symptoms by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides SS symptoms of treatment algorithms and treatment guidelines for SS symptoms in the US, Europe, and Japan.
Sjogren’s syndrome (SS) Epidemiology
The Sjogren’s syndrome symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Sjogren’s syndrome (SS) epidemiology segmented as the Diagnosed Prevalent Cases of Sjögren’s syndrome, Gender-Specific Cases of Sjögren’s syndrome, Type-Specific Cases of Sjögren’s syndrome, Severity-Specific Cases of Sjögren’s syndrome. The report includes the prevalent scenario of SS symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.
Country Wise- Sjogren’s syndrome (SS) Epidemiology
The epidemiology segment also provides the Sjogren’s syndrome (SS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The total prevalent cases of Sjogren’s syndrome (SS) in 7MM countries were estimated to be 3,179,223 cases in 2017.
Sjogren’s syndrome (SS) Drug Chapters
The drug chapter segment of the Sjogren’s syndrome (SS) report encloses the detailed analysis of SS marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sjogren’s syndrome (SS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The therapeutic market size of Sjögren’s syndrome is mainly accounted by symptomatic treatment including local therapies, systemic therapies, and immunosuppressants (Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid). Moreover, Biological therapies such as Rituximab is in extensive use for the US market.
Products detail in the report…
Sjogren’s syndrome (SS) Emerging Drugs
VAY736 (Ianalumab) (Novartis/MorphoSys)
It is a novel, intravenous, defucosylated, monoclonal antibody that targets the human B cell-activating factor (BAFF) of the TNF family. It is engineered to effectively eliminate B cells from circulation in vivo by antibody-dependent cellular cytotoxicity (ADCC). The ADCC activity of Ianalumab is greatly enhanced by the elimination of fucose residues from the carbohydrate moiety attached to the Fc part of the antibody. The molecule is being developed by the Novartis in partnership with MorphoSys as an antibody-based therapy. It is currently in Phase II clinical studies for the treatment of primary Sjögren's Syndrome.
Products detail in the report…
Sjogren’s syndrome (SS) Market Outlook
The Sjogren’s syndrome (SS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted Sjogren’s syndrome (SS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Sjogren’s syndrome (SS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Sjogren’s syndrome (SS) market in 7MM is expected to change in the study period 2017–2030.
The local therapies mainly include pilocarpine, cevimeline, topical fluoride, topical cyclosporine, autologous serum eye drops, and others. Systemic therapy mainly uses corticosteroids, hydroxychloroquine, and immunosuppressants. Methotrexate (MTX), Cyclosporine A, Azathioprine, Leflunomide, and Mycophenolic acid are also commonly used DMARDs. Biological therapy with Rituximab is in extensive use for the US market. Along with this, TNF- alpha inhibitors, BAFF, and others are in the development.
Key Findings
This section includes a glimpse of the Sjogren’s syndrome (SS) market in 7MM. The market size of SS in the seven major markets was found to be USD 1,699.8 Million in 2017.

The United States Market Outlook
This section provides a total of Sjogren’s syndrome (SS) market size and market size by therapies in the United States.
The United States accounts for the highest market size of SS in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Local therapy generally includes the treatment of sicca symptoms. For the treatment of dry eyes, tear substitution therapy consisting of high-viscosity eye drops and gels, in combination with oral mucolytic agents to dissolve mucus, is the mainstay treatment. Patients with Sjögren’s syndrome associated severe or refractory keratoconjunctivitis sicca might require a short-term course of topical anti-inflammatory agents such as topical cyclosporine.
Drugs with a systemic effect, secretagogues, such as pilocarpine and cevimeline, are approved by the US FDA for the treatment of dry eyes and mouth in patients with Sjögren’s syndrome. Both drugs are muscarinic receptor agonists and induce a transient increase in salivary and lacrimal gland outputs in patients with some residual functional glandular tissue. Common adverse effects of these drugs include sweating, flushing, and the urgent need for urination and gastrointestinal discomfort, which might limit their clinical application.
EU-5 Countries: Market Outlook
The total Sjogren’s syndrome (SS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The therapeutic effect of hydroxychloroquine is based on the inhibition of TLR signaling, which affects the innate immune response by reducing the production of proinflammatory cytokines, such as type I IFNs, and other serological parameters. It is used as maintenance therapy in SS, based on the reduction of symptoms and improved serological parameters in patients with SLE and rheumatoid arthritis.
Methothrexate (MTX) is used in the treatment of arthritis in Sjögren’s syndrome patients. Moreover, the usefulness of other immunosuppressive agents (such as cyclosporine A, azathioprine, methotrexate, leflunomide, and mycophenolic acid) has been evaluated in a small cohort of patients with SS. However, all these have high rates of adverse events
Japan Market Outlook
The total of Sjogren’s syndrome (SS) market size and market size by therapies in Japan are also mentioned.
Sjogren’s syndrome (SS) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Sjogren’s syndrome (SS) market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Sjogren’s syndrome (SS) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Sjogren’s syndrome (SS) key players involved in developing targeted therapeutics.
Major players include Belimumab (GlaxoSmithKline), RSLV-132 (Resolve Therapeutics), VAY736 (Novartis/MorphoSys), CFZ533 (Novartis), LOU-064 (Novartis), RC18 (Remgen), VIB4920 (Viela Bio), Branebrutinib (Bristol Myers Squib), Lacripep (TearSolutions) and others.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Sjogren’s syndrome (SS) emerging therapies.
Reimbursement Scenario in Sjogren’s syndrome (SS)
For Sjögren’s Syndrome, no remitting agent exists and the treatment includes symptom palliation, prevention of complications. The frequent occurrence of oral and ocular complications mandates a multidisciplinary approach. For rheumatologists, proper selection of patients for immunosuppressive therapy is quite a challenge to optimize care. Unfortunately, the paucity of well-designed, controlled studies in the Sjögren’s Syndrome medical and dental literature frequently leaves the clinician with little guidance. Therefore, the approach to treating SS in the United States has differed widely among various institutions and providers.
Several studies have documented that quality of life (QOL) is diminished in primary Sjögren’s Syndrome (PSS) and found overall end-organ damage, as well as functional disability, comparable with lupus. Various studies found that the substantial use of healthcare services, with a mean annual total direct cost per Sjögren’s patient, ranging between £2200 in the UK and USD 20, 000 in the USA.
KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in Sjogren’s syndrome (SS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Sjogren’s syndrome (SS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive & Market Intelligence analysis of the Sjogren’s syndrome (SS) Market by using various Competitive Intelligence tools that includes – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
• The report covers the descriptive overview of Sjogren’s syndrome (SS), explaining its causes, signs and symptoms, pathophysiology and currently available therapies
• Comprehensive insight has been provided into the Sjogren’s syndrome (SS) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Sjogren’s syndrome (SS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Sjogren’s syndrome (SS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Sjogren’s syndrome (SS) market
Report Highlights
• In the coming years, Sjogren’s syndrome (SS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Sjogren’s syndrome (SS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for SS. Launch of emerging therapies will significantly impact the Sjogren’s syndrome (SS) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for SS.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Sjogren’s syndrome (SS) Report Insights
• Patient Population
• Therapeutic Approaches
• Sjogren’s syndrome (SS) Pipeline Analysis
• Sjogren’s syndrome (SS) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Sjogren’s syndrome (SS) Report Key Strengths
• 11 Years Forecast
• 7MM Coverage
• Sjogren’s syndrome (SS) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Sjogren’s syndrome (SS) Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
Key Questions
Market Insights:
• What were the Sjogren’s syndrome (SS) Market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Sjogren’s syndrome (SS) total market Size as well as market Size by therapies across the 7MM during the forecast period (2017–2030)?
• What are the key findings of the market across 7MM and which country will have the largest Sjogren’s syndrome (SS) market Size during the forecast period (2017–2030)?
• At what CAGR, the Sjogren’s syndrome (SS) market is expected to grow in 7MM during the forecast period (2017–2030)?
• What would be the Sjogren’s syndrome (SS) market outlook across the 7MM during the forecast period (2017–2030)?
• What would be the Sjogren’s syndrome (SS) market growth till 2030 and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of the Sjogren’s syndrome (SS)?
• What is the historical Sjogren’s syndrome (SS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What would be the forecasted patient pool of Sjogren’s syndrome (SS) in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan?
• What will be the growth opportunities in the 7MM concerning the patient population about Sjogren’s syndrome (SS)?
• Out of all 7MM countries, which country would have the highest prevalent population of Sjogren’s syndrome (SS) during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2017–2030)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Sjogren’s syndrome (SS)?
• What are the current treatment guidelines for the treatment of Sjogren’s syndrome (SS) in the USA, Europe, and Japan?
• What are the Sjogren’s syndrome (SS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Sjogren’s syndrome (SS)?
• How many therapies are developed by each company for the treatment of Sjogren’s syndrome (SS)?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Sjogren’s syndrome (SS)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sjogren’s syndrome (SS) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sjogren’s syndrome (SS) and their status?
• What are the key designations that have been granted for the emerging therapies for Sjogren’s syndrome (SS)?
• What are the global historical and forecasted market of Sjogren’s syndrome (SS)?
Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Sjogren’s syndrome (SS) market
• To understand the future market competition in the Sjogren’s syndrome (SS) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Sjogren’s syndrome (SS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Sjogren’s syndrome (SS) market
• To understand the future market competition in the Sjogren’s syndrome (SS) market